Quick Answer
IONIS PHARMACEUTICALS INC reported Total Revenue of $943.71 million for fiscal year 2025.
IONIS PHARMACEUTICALS INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $943.71M +33.8% |
$705.14M -10.5% |
$787.65M +34.1% |
$587.37M -27.5% |
$810.46M +11.1% |
$729.26M -35.0% |
| Revenue (ASC 606) | $943.71M +33.8% |
$705.14M -10.5% |
$787.65M +34.1% |
$587.37M -27.5% |
$810.46M +11.1% |
$729.26M -35.0% |
| Net Income | -$381.39M +16.0% |
-$453.90M -23.9% |
-$366.29M -35.8% |
-$269.72M -843.2% |
-$28.60M +93.6% |
-$444.26M -259.7% |
| Diluted EPS | -$2.38 +21.7% |
-$3.04 -18.8% |
-$2.56 -34.7% |
-$1.90 -850.0% |
-$0.20 +93.7% |
-$3.18 -267.4% |
| Total Assets | $3.52B +17.3% |
$3.00B +0.5% |
$2.99B +18.0% |
$2.53B -3.0% |
$2.61B +9.3% |
$2.39B -26.1% |
| Cash and Equivalents | $372.26M +53.8% |
$242.08M -39.4% |
$399.27M +44.4% |
$276.47M -68.2% |
$869.19M +118.6% |
$397.66M -41.8% |
| Stockholders Equity | $489.09M -16.9% |
$588.35M +52.2% |
$386.69M -32.5% |
$572.89M -25.8% |
$771.74M +3.8% |
$743.28M -49.5% |
| R&D Expense | $915.62M +1.6% |
$901.53M +0.2% |
$899.62M | — | — | — |
| Operating Income | -$381.68M +19.7% |
-$475.08M -34.3% |
-$353.73M +13.8% |
-$410.19M -1258.9% |
-$30.19M +82.5% |
-$172.08M -147.0% |
| Shares Outstanding | 163.30M +3.4% |
157.91M +9.4% |
144.34M +1.6% |
142.06M +0.6% |
141.21M +0.6% |
140.37M +0.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $156.72M | +17.1% | -65.3% |
| Revenue (ASC 606) | September 30, 2025 | $156.72M | +17.1% | -65.3% |
| Net Income | September 30, 2025 | -$128.61M | +8.5% | -204.1% |
| Diluted EPS | September 30, 2025 | -$0.80 | +15.8% | -214.3% |
| Total Assets | September 30, 2025 | $3.03B | -1.6% | +1.6% |
| Cash and Equivalents | September 30, 2025 | $338.34M | +1.1% | +13.8% |
| Stockholders Equity | September 30, 2025 | $617.97M | -6.7% | -2.2% |
| R&D Expense | June 30, 2013 | $42.63M | +5.4% | +11.3% |
| Operating Income | September 30, 2025 | -$160.18M | -7.8% | -214.6% |
| Shares Outstanding | September 30, 2025 | 161.14M | +2.1% | +1.2% |
- IONIS PHARMACEUTICALS INC reported Total Revenue of $943.71 million for fiscal year 2025.
- IONIS PHARMACEUTICALS INC showed an increase of +33.8% in Total Revenue compared to the prior fiscal year.
- IONIS PHARMACEUTICALS INC reported Revenue (ASC 606) of $943.71 million for fiscal year 2025.
- IONIS PHARMACEUTICALS INC showed an increase of +33.8% in Revenue (ASC 606) compared to the prior fiscal year.
- IONIS PHARMACEUTICALS INC reported Net Income of -$381.39 million for fiscal year 2025.
- IONIS PHARMACEUTICALS INC showed an increase of +16.0% in Net Income compared to the prior fiscal year.
- IONIS PHARMACEUTICALS INC reported Diluted EPS of $2.38 per share (loss) for fiscal year 2025.
- IONIS PHARMACEUTICALS INC showed an increase of +21.7% in Diluted EPS compared to the prior fiscal year.
- IONIS PHARMACEUTICALS INC reported Total Assets of $3.52 billion for fiscal year 2025.
- IONIS PHARMACEUTICALS INC showed an increase of +17.3% in Total Assets compared to the prior fiscal year.
- IONIS PHARMACEUTICALS INC reported Cash and Equivalents of $372.26 million for fiscal year 2025.
- IONIS PHARMACEUTICALS INC showed an increase of +53.8% in Cash and Equivalents compared to the prior fiscal year.
- IONIS PHARMACEUTICALS INC reported Stockholders Equity of $489.09 million for fiscal year 2025.
- IONIS PHARMACEUTICALS INC showed a decrease of -16.9% in Stockholders Equity compared to the prior fiscal year.
- IONIS PHARMACEUTICALS INC reported R&D Expense of $915.62 million for fiscal year 2025.
- IONIS PHARMACEUTICALS INC showed an increase of +1.6% in R&D Expense compared to the prior fiscal year.
- IONIS PHARMACEUTICALS INC reported Operating Income of -$381.68 million for fiscal year 2025.
- IONIS PHARMACEUTICALS INC showed an increase of +19.7% in Operating Income compared to the prior fiscal year.
- IONIS PHARMACEUTICALS INC reported Shares Outstanding of 163.30 million shares for fiscal year 2025.
- IONIS PHARMACEUTICALS INC showed an increase of +3.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: